Akero Therapeutics Inc (NASDAQ:AKRO) has a beta value of -0.14 and has seen 5.23 million shares traded in the last trading session. The company, currently valued at $3.59B, closed the last trade at $51.47 per share which meant it lost -$0.24 on the day or -0.46% during that session. The AKRO stock price is -13.46% off its 52-week high price of $58.40 and 70.24% above the 52-week low of $15.32. If we look at the company’s 10-day average daily trading volume, we find that it stood at 2.48 million shares traded. The 3-month trading volume is 962.62K shares.
The consensus among analysts is that Akero Therapeutics Inc (AKRO) is Buy stock at the moment, with a recommendation rating of 1.17. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 4 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -1.13.
Akero Therapeutics Inc (NASDAQ:AKRO) trade information
Sporting -0.46% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the AKRO stock price touched $51.47 or saw a rise of 11.87%. Year-to-date, Akero Therapeutics Inc shares have moved 85.01%, while the 5-day performance has seen it change 101.05%. Over the past 30 days, the shares of Akero Therapeutics Inc (NASDAQ:AKRO) have changed 80.22%. Short interest in the company has seen 3.35 million shares shorted with days to cover at 4.23.
Wall Street analysts have a consensus price target for the stock at $50, which means that the shares’ value could drop -2.94% from current levels. The projected low price target is $50.0 while the price target rests at a high of $50.0. In that case, then, we find that the current price level is 2.86% off the targeted high while a plunge would see the stock lose 2.86% from current levels.
Akero Therapeutics Inc (AKRO) estimates and forecasts
Figures show that Akero Therapeutics Inc shares have underperformed across the wider relevant industry. The company’s shares have gained 83.04% over the past 6 months, with this year growth rate of -38.06%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.
If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 1.03% over the past 5 years. Earnings growth for 2025 is a modest -39.67% while over the next 5 years, the company’s earnings are expected to decrease by -17.56%.
AKRO Dividends
Akero Therapeutics Inc is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.
Akero Therapeutics Inc (NASDAQ:AKRO)’s Major holders
Insiders own 5.58% of the company shares, while shares held by institutions stand at 106.52% with a share float percentage of 112.81%. Investors are also buoyed by the number of investors in a company, with Akero Therapeutics Inc having a total of 249.0 institutions that hold shares in the company. The top two institutional holders are JANUS HENDERSON GROUP PLC with over 6.88 million shares worth more than $161.28 million. As of 2024-06-30, JANUS HENDERSON GROUP PLC held 11.5942% of shares outstanding.
The other major institutional holder is BLACKROCK INC., with the holding of over 5.59 million shares as of 2024-06-30. The firm’s total holdings are worth over $131.06 million and represent 9.4197% of shares outstanding.
Also the top two Mutual Funds that are holding company’s shares are Vanguard Specialized-Health Care Fund and Janus Henderson Global Life Sciences Fund . As of Oct 31, 2024 , the former fund manager holds about 6.31% shares in the company for having 4.4 shares of worth $226.53 million while later fund manager owns 2.02 shares of worth $103.95 million as of Sep 30, 2024 , which makes it owner of about 2.89% of company’s outstanding stock.
